The Drug Enforcement Administration on Monday filed a draft Federal Register notice laying out proposed 2027 annual production quotas (APQs) for Schedule I and II substances. The agency is moving to dramatically increase the amount of certain psychedelics that can be legally produced in the U.S. next year for medical, scientific, research and industrial purposes.
DEA is proposing an especially large increase in legal ibogaine production, from 210 grams this year to 12,002 grams in 2027. MDMA production would rise from 12,000 grams in 2026 to 33,296 grams next year.
“DEA is proposing higher APQs than the 2026 proposed revised APQs for the following schedule I controlled substances: 3,4-Methylenedioxymethamphetamine (MDMA) and ibogaine to support manufacturing activities related to the increased level of research and clinical trials being conducted with these substances for potential treatment of conditions including post-traumatic stress disorder (PTSD) and depression,” the filing says.
The agency is also proposing to increase legal production of the psychedelic psilocybin from 50,000 grams this year to 60,000 grams next year. Its related chemical psilocyn would rise from 80,000 grams in 2026 to 93,600 grams in 2027.
DEA said the move “aligns with” executive orders issued by President Donald Trump, including one focused on boosting research on and access to psychedelics that he signed in April.
For marijuana, DEA is proposing to keep production of it and related cannabinoids for Schedule I purposes at existing 2026 levels. Those levels are 6,675,000 grams of cannabis, 1,000,000 grams of marijuana extract, 1,523,040 grams of delta-9-THC and 1,166,130 grams of all other THC.
The agency noted in the Federal Register filing that state-licensed medical cannabis and medical marijuana products approved by the Food and Drug Administration have been moved to Schedule III under an order signed earlier this year by Attorney General Todd Blanche.
DEA has accordingly assigned new unique drug codes for newly rescheduled marijuana and cannabinoids. “DEA is currently in the process of registering the manufacturers and distributors who will be handling the substances that have been moved to schedule III under the CSA as outlined in the final rule,” it said.
The agency is assessing data sources and methodologies to determine the most reliable and relevant datasets for estimating the United States’ legitimate need and production requirements for rescheduled marijuana and cannabinoids.
Because of that ongoing work, the new filing only reflects marijuana-related quota levels for cannabis that remains in Schedule I for research purposes.
“A separate notice will be published in the Federal Register once the proposed APQs for the schedule III substances…are determined,” DEA said. A separate hearing is underway to consider the process of moving non-medical marijuana to Schedule III as well.
Once the new Federal Register notice on production quotas is formally published on Wednesday, the agency will accept public comments on the proposal for a period of 30 days.
Agencies Destroy 458 Acres Of Illicit Cannabis On November 7, the Narcotics Control Bureau (NCB), the Sashastra Seema Bal (SSB),…
Goodwin Signals Openness to Reform Options Texas's incoming Democratic lieutenant governor says there are multiple paths forward for cannabis reform…
Senate Shift Creates Legislative Opening Pennsylvania Democrats will hold single-party legislative control next year, raising expectations that lawmakers will pass…
Study Puts Calibration Vials to the Test A five-lab study found that some cannabis calibration vials measured differently from the…
Missouri Attorney General Sues Four Retailers Missouri Attorney General Catherine Hanaway announced last week that her office is suing four…
New York Ethics Body Rules Against Judge License New York's judicial ethics authority has issued an advisory opinion concluding that…
